Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial

Objective

To compare the efficacy of bimekizumab (BKZ) versus secukinumab (SEC) through 48 weeks for the treatment of nail psoriasis, including complete nail clearance, in patients with moderate to severe plaque psoriasis who had nail involvement at baseline.

To compare modified Nail Psoriasis Severity Index (mNAPSI) sub-score complete clearance rates at Week 16 and Week 48 in patients treated with BKZ versus SEC.

Background

- Psoriatic lesions in highly visible areas, including the nails, disproportionately affect patients' health-related quality of life.¹
- Here, we assessed mNAPSI total scores and mNAPSI sub-scores among patients with baseline mNAPSI >10 in the BE RADIANT phase 3b trial.²

Methods

- In BE RADIANT, patients were randomized to BKZ 320 mg every 4 weeks (Q4W) or SEC 300 mg weekly to Week 4 then Q4W.² From Week 16, BKZ-randomized patients received BKZ Q4W or Q8W (Figure 1).
- Modified Nail Psoriasis Severity Index (mNAPSI) scores (total and sub-scores) are reported for BKZ- and SEC-randomized patients who had baseline mNAPSI >10 and entered the maintenance period (Table 1).
- Results for BKZ-treated patients are reported as BKZ Total, comprising all patients who received ≥ 1 BKZ dose in the maintenance period (combined Q4W/Q4W and Q4W/Q8W groups).
- Missing data were handled using non-responder imputation (NRI). Modified non-responder imputation (mNRI) and observed cases (OC) are also reported.

Results


- In total, 116 BKZ-treated and 99 SEC-treated patients had baseline mNAPSI >10 and entered the maintenance period (Table 1); 37.1% and 40.4% of BKZ- and SEC-treated patients achieved mNAPSI ≤ 2 at Week 16, respectively; 75.0% and 59.6% achieved mNAPSI \leq 2 at Week 48 (Figure 2).
- From Weeks 16–48, mNAPSI 0 (clear) response rates increased from 26.7% to 70.7% with BKZ, and 33.3% to 53.5% with SEC.
- At Week 16, 36.6% of BKZ-treated and 41.9% of SEC-treated patients achieved a nail pitting sub-score of 0 (clear), increasing to 78.2% and 59.3% of patients at Week 48 (Figure 3).
- Of BKZ-treated patients at Week 16, 65.2% achieved a nail plate crumbling sub-score of 0 (clear), vs 69.6% of SEC-treated patients. Achievement increased to 85.5% and 75.0% at Week 48, respectively (Figure 3).
- Of BKZ-treated patients at Week 16, 69.5% achieved a leukonychia sub-score of 0 (clear), vs 70.7% of SEC-treated patients. Achievement increased to 79.7% and 69.0% of patients at Week 48 (Figure 3).


Conclusions

Complete nail clearance (mNAPSI 0) was achieved in numerically higher proportions of bimekizumab-treated patients than secukinumab-treated patients by Week 48.

At Week 48, bimekizumab-treated patients showed numerically higher rates of complete clearance for all mNAPSI sub-scores compared with secukinumab-treated patients, with the exception of red spots in lunula.

Summary





mNAPSI >10

Age (years), mean <u>+</u> SD **Male**, n (%) **White**, n (%) Weight (kg), mean <u>+</u> SD Duration of psoriasis (years), mean + SD **PASI**, mean <u>+</u> SD **BSA (%)**, mean <u>+</u> SD **IGA**, n (%) 3: moderate 4: severe **DLQI total score**, mean <u>+</u> SD **mNAPSI**, mean <u>+</u> SD Onycholysis/oil-drop dyschromia Nail plate crumbling Pitting Leukonychia Nail bed hyperkeratosis Splinter hemorrhages

Any prior biologic therapy, n (%)

Red spots in lunula

[a] Data were pooled for all patients who received >1 BKZ dose at Week 16 or later (BKZ Total). BKZ Total included all patients with mNAPSI>10 at baseline who were treated with BKZ Q4W/Q4W (n=42) or with BKZ Q4W/Q8W (n=74), combined Only patients with mNAPSI >10 at baseline and who entered the maintenance period of BE RADIANT were included in this analysis. A score of 0 indicates clear nails. BKZ: bimekizumab; BSA: body surface area; DLQI: Dermatology Life Quality Index; MRI: non-responder imputation; SEC: secukinumab. BKZ: bimekizumab; BSA: body surface area; DLQI: Dermatology Life Quality Index; MRI: non-responder imputation; SEC: secukinumab. BKZ: bimekizumab; BKZ: bimekizumab; BSA: body surface area; DLQI: Dermatology Life Quality Index; MRI: non-responder imputation; SEC: secukinumab. BKZ: bimekizumab; BKZ: bimekizumab; BSA: body surface area; DLQI: Dermatology Life Quality Index; MRI: non-responder imputation; SEC: secukinumab. BKZ: bimekizumab; BKZ: bimekizumab;

e E Bernatology, E Bern ⁷UCB Pharma, Slough, UK; ⁸UCB Pharma, Morrisville, NC, USA; ⁹UCB Pharma, Monheim, Germany; ¹⁰UCB Pharma, Brussels, Belgium; ¹¹Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA; trace black bl Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, and UCB Pharma, and UCB Pharma, and Visory board member and consultant for: Amgen, AnaptysBio, Bristol Myers Squibb, MoonLake Immunotherapeutics, Eli Lilly, Janssen, Novartis, and UCB Pharma, and Visory board member and consultant for: Amgen, AnaptysBio, Bristol Myers Squibb, MoonLake Immunotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Bristol My Ei Lilly, Galderma, Berker, Consultant or advisory boards, From AbbVie, Actelion, Bristol Myers Squibb, Calderma, GSK, Incyte, Janssen-Cilag, LEO Pharma, Menlo Therapeutics, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, and Roche Posay; honoraria for serving on advisory boards, Ei Lilly, Galderma, GSK, Incyte, Janssen-Cilag, LEO Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pharma, GSK, Incyte, Janssen-Cilag, MSD, Novartis, Pfizer, and UCB Pha End Stere and UCB Pharma. Bistol Myers Squibb, Celgene, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. Biogen, Bistol Myers Squibb, Celgene, Eli Lilly, Incyte, LEO Pharma. B the investigators and their teams who contributed to this study. The authors acknowledgements: We would like to thank the patients and their teams who contributed to this study. The authors acknowledge Joe Dixon, PhD, UCB Pharma, Valeant, and Verrica. Acknowledge Joe Dixon, PhD, UCB Pharma, Valeant, and their teams who contributed to this study. The authors acknowledgements: We would like to thank the patients and their teams who contributed to this study. The authors acknowledge Joe Dixon, PhD, UCB Pharma, Valeant, and their teams who contributed to this study. The authors acknowledge Joe Dixon, PhD, UCB Pharma, Valeant, and their teams who contributed to this study. The authors acknowledge Joe Dixon, PhD, UCB Pharma, Valeant, and their teams who contributed to this study. The authors acknowledge Joe Dixon, PhD, UCB Pharma, Valeant, and their teams who contributed to this study. The authors acknowledge Joe Dixon, PhD, UCB Pharma, Valeant, and their teams who contributed to this study. The authors acknowledge Joe Dixon, PhD, UCB Pharma, Valeant, and their teams who contributed to this study. The authors acknowledge Joe Dixon, PhD, UCB Pharma, Valeant, and their teams who contributed to the creative team at Costello Medical, Cambridge, UK, for medical for graphic design assistance and the creative team at Costello Medical, Cambridge, UK, for medical for graphic design assistance and the creative team at Costello Medical, Cambridge, UK, for medical, Cambridge, UK, f This study was funded by UCB Pharma. All costs associated with development of this presentation were funded by UCB Pharma.

0-3 for:

- Onycholysis/oil-drop dyschromia
- Nail plate crumbling
- Pitting

0 (no) or 1 (yes) for:


- Leukonychia
- Nail bed hyperkeratosis
- Splinter hemorrhages
- Red spots in lunula


mNAPSI is the sum of the scores for all nails (range: 0–130, 0 indicates clear nails)

Here, we assessed mNAPSI total scores and mNAPSI sub-scores among patients with baseline

Complete nail clearance (mNAPSI 0) was achieved in numerically higher proportions of BKZ-treated patients than SEC-treated patients by Week 48 [a] The mNAPSI has demonstrated superior interrater variability and correlations with patient and physician global assessments versus the NAPSI.³

Table 1 Baseline characteristics: included patients










Figure 3 Complete clearance of mNAPSI sub-scores at Week 16 and Week 48 in patients with baseline mNAPSI >10 and sub-score >0 (NRI)

Kilian Eyerich,¹ Alice B. Gottlieb,² Stefano Piaserico,³ Stefan Beissert,⁴ Melinda Gooderham,⁵ Brian Kirby,⁶ Nicola Tilt,⁷ Cynthia Madden,⁸ Susanne Wiegratz,⁹ Dirk de Cuyper,¹⁰ Joseph F. Merola,¹¹ Boni Elewski¹²

UCBposters.com/ACR2 Poster ID: 225 Link expiratio

November 29, 202

